Ontology highlight
ABSTRACT:
SUBMITTER: Tsang RY
PROVIDER: S-EPMC3251862 | biostudies-literature | 2012 Jan
REPOSITORIES: biostudies-literature
British journal of cancer 20120101 1
The use of trastuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) alteration present in 25 to 30% of breast cancers, has been associated with improved survival outcomes in both the adjuvant and metastatic settings. However, despite the robust clinical efficacy of trastuzumab in HER2-positive metastatic breast cancer (MBC), primary and secondary resistance remains a clinical challenge. Although lapatinib has demonstrated modest activity in this setting ...[more]